Hologic logo, dark blue
Hologic logo, dark blue

Making a world of difference, together

The ThinPrep Pap test, here for you now and for the future of cervical health

Over 25 years of experience in cervical health screening, working in partnership with our customers, has enabled us to create standardisation and consistency for your screening services. This is backed by over 250 clinical studies and >700 million Pap tests processed worldwide.1-18

Hologic’s cervical health screening solution provides a comprehensive, fully-automated and proven solution which delivers validated clinical performance and supports a cost-effective approach for your healthcare system; whatever your screening algorithm.19-41

Click below to learn more about how our cervical health screening solution can benefit your facility.

Learn More

Why Hologic?

Consolidate, automate and future-proof workflow to deliver efficiency and cost savings, whilst maintaining high clinical performance and your reputation as leaders in cervical health screening innovation.19-41

We take pride in delivering:

  • Trusted and collaborative long-term relationships
  • Continuous investment in the future of cervical health
  • A complete solution for your hospital or laboratory
  • Workflow efficiencies and reduced labour through consolidation of technology whilst maintaining excellent throughput and patient outcomes

You can also be assured that we are continuing to innovate and invest in the future of Cervical Health and are pleased to introduce the Genius™ Digital Diagnostics System.

The Genius Digital Diagnostics System combines the power of a deep learning-based artificial intelligence (AI) algorithm with advanced volumetric imaging technology to help identify pre-cancerous lesions and cervical cancer cells in women.

 
 

Contact us today to find out how your institution can benefit from world leading cytology innovation and be at the forefront of women's health.

Thin Prep Leader Footer

Hologic Hub Ltd (Heron House, Oaks Business park, Crewe Road, Manchester M23 9HZ, UK) is the data controller responsible for this contact form. Read our Privacy Policy here. If you have any questions about this privacy notice or our data protection practices, please send an e-mail to data.privacy@hologic.com

Hologic, here for you now and for the future of cervical health.



 

Authorised Representative

Hologic BV

Da Vincilaan 5

1930 Zaventem

Belgium

The content on this page is directed to audiences in Europe only.

References: 1. Ikenberg H et al. Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study. J Natl Cancer Inst. 2013; 105:1550–57. 2. Bernstein SJ et al. Liquid-based cervical cytologic smear study and conventional Papanicolaou smears: a metaanalysis of prospective studies comparing cytologic diagnosis and sample adequacy. Am J Obstet Gynecol. 2001; 185:308–317. 3. Abulafia O et al. Performance of ThinPrep liquid-based cervical cytology in comparison with conventionally prepared Papanicolaou smears: a quantitative survey. Gyn Oncol. 2003; 90:137–144. 4. Hutchinson M, et al. Homogeneous Sampling Accounts for the Increased Diagnostic Accuracy Using the ThinPrep Processor. Am J Clin Pathol. 1994;101(2):215-9. 5. Klinkhamer, et al. Liquid-based Cervical Cytology. Cancer Cytopathol. 2003;99(5):263-71. 6. PrepStain System [product insert]. 779-07085-00, Rev. F. Burlington, NC: TriPath Imaging, Inc., 2011. 7. Eversole GM, et al. Practices of participants in the college of American pathologists interlaboratory comparison program in cervicovaginal cytology, 2006. Arch Pathol Lab Med. 2010;134(3):331-5. 8. Schorge JO, et al. ThinPrep detection of cervical and endometrial adenocarcinoma: a retrospective cohort study. Cancer Cytopathol. 2002;96:338-343. 9. Bai H, et al. ThinPrep Pap Test promotes detection of glandular lesions of the endocervix. Diagn Cytopathol. 2000;23:19-22. 10. Carpenter AB, et al. ThinPrep Pap Test: Performance biopsy follow-up in a university hospital. Cancer. 1999;87:105-112. 11. Guidos BJ, et al. Detection of endometrial adenocarcinoma with the ThinPrep Pap Test. Diagn Cytopathol. 2000;23:260-265. 12. Ashfaq R, et al. ThinPrep Pap Test: Accuracy for glandular disease. Acta Cytol. 1999;43:81-85. 13. Wang N, et al. Histologic follow-up of atypical endocervical cells. Liquidbased, thin-layer preparation vs. conventional pap smear. Acta Cytol. 2002;46:453-457. 14. Medical Associations and Advocacy Groups Acknowledge Importance of New FDA Claims for ThinPrep Pap Test [press release]. Marlborough, MA: Cytyc Corporation; September 15, 2005. 15. Dziura B, et al. Performance of an imaging system vs. manual screening in the detection of squamous intra epithelial lesions of the uterine cervix. Acta Cytol. 2006;50(3):309-11. 16. Lozano R. Comparison of computer-assisted and manual screening of cervical cytology. Gynecol Oncol. 2007;104(1):134-8. 17. Miller FS, et al. Implementation of the ThinPrep imaging system in a high-volume metropolitan laboratory. Diagn Cytopathol. 2007;35(4):213-7. 18. Klug SJ, et al. A randomized trial comparing conventional cytology to liquid-based cytology and computer assistance. Int J Cancer. 2012;132(12):2849-57. 19. Arbyn et al.Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening? Clin Microbiol Infect. 2015 21(9):817-26 20. Haedecki J & Iftner T. A review of the clinical performance of the Aptima HPV assay. Journal of Clinical Virology 76 (2016) S40–S48 21. Iftner et al. Longitudinal Clinical Performance of the RNA-Based Aptima Human Papillomavirus (AHPV) Assay in Comparison to the DNA-Based Hybrid Capture 2 HPV Test in Two Consecutive Screening Rounds with a 6-Year Interval in Germany. J Clin Microbiol 2019 57(1) e01177-18. 22. Cook DA et al (FOCAL),Aptima HPV Assay versus Hybrid Capture ® 2 HPV test for primary cervical cancer screening in the HPV FOCAL trial. Journal of Clinical Virology 87 (2017) 23–29. 23. Cook DA et al. Comparative performance of human papillomavirus messenger RNA versus DNA screening tests at baseline and 48 months in the HPV FOCAL trial. J Clin Virol. 2018; 108:32-37. 24. Forslund O et al.HPV-mRNA and HPV-DNA detection in samples taken up to seven years before severe dysplasia of cervix uteri. 2018 Int. J. Cancer: 144, 1073–1081. 25. Szarewski A. et al. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smearsCancer Epidemiol Biomarkers. Prev. 2008;17(11):3033–42. 26. Reuschenbach M. et al.Performance of p16INK4a-cytology, HPV mRNA, and HPV DNA testing to identify high grade cervical dysplasia in women with abnormal screening results. Gynecol Oncol. 2010;119(1):98–105. 27. Clad A. et al. Performance of the Aptima high-risk human papillomavirus mRNA assay in a referral population in comparison with Hybrid Capture 2 and cytology. J Clin Microbiol. 2011;49(3):1071–76. 28. Ratnam S. et al. Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 Assay but more specific at detecting cervical precancer and cancer. J Clin Microbiol. 2011;49(2):557–64. 29. Ovestad I. et al. Comparison of different commercial methods for HPV detection in follow-up cytology after ASCUS/LSIL, prediction of CIN2-3 in follow up biopsies and spontaneous regression of CIN2-3. Gynecol Oncol. 2011;123(2):278–283. 30. Szarewski et al. Comparison of seven tests for high-grade cervical intraepithelial neoplasia in women with abnormal smears: the Predictors 2 study. J Clin Microbiol. 2012;50(6):1867–73 31. Eaton, et al. Paper presented at: 28th International Papillomavirus Conference; 2012; San Juan, Puerto Rico. 32. Cuschieri K. et al. Clinical performance of RNA and DNA based HPV testing in a colposcopy setting: Influence of assay target, cut off and age. J Clin Virol. 2014;59(2):104–8. 33. Cubie H. et al. Evaluation of commercial HPV assays in the context of post-treatment follow-up: Scottish Test of Cure Study (STOCS-H) J Clin Pathol. 2014;67(6):458–63. 34. Wu et al. Human papillomavirus messenger RNA assay for cervical cancer screening: the Shenzhen Cervical Cancer Screening Trial I. Intl J Gynecol Cancer. 2010;20(8):1411–14. 35. Monsonego J. et al. Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE study. Intl J Cancer. 2011;129(3):691–701. 36. Cuzick J. et al. Comparing the performance of six human papillomavirus tests in a screening population. Br J Cancer. 2013;108:908–13. 37. Nieves L. et al. Primary cervical cancer screening and triage using an mRNA human papillomavirus assay and visual inspection. Int J Gynecol Cancer. 2013;23(3):513–518. 38. Guan P, et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Intl. J Cancer. 2012 131(10):2349–59. 39. Petticrew et al. Health Technology Assessment. 2000; Available at: https://www.journalslibrary.nihr.ac.uk/hta/hta4050#/abstract. 40. Centers for Disease Control and Prevention. Cervical Cancer is Preventable. https://www.cdc.gov/vitalsigns/cervical-cancer/index.html. 41. Curran D, Stigleman S, Neher J. Clinical Inquries. Should we discontinue Pap smear screening in women aged>65 years? J Family Practice 2004; 53:308-31.

*The views and opinions expressed in this presentation are those of the author and do not necessarily reflect the opinion of Hologic Inc. or any of its affiliated companies

** Not for sale in all markets. Contact your Hologic Sales representative for more details